Evidence map›Paper›PMID 24305703›Full record

ArticleNeuro-oncology2014

MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation.

Sabit Delic, Nadine Lottmann, Anja Stelzl, Franziska Liesenberg, Marietta Wolter, Silke Götze, Marc Zapatka, Yuzuru Shiio, Michael C Sabel, Jörg Felsberg and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 89 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Longitudinal [Biomedicines · 2022
    Article
  8. Article
  9. Review
  10. Review
  11. The Role of Neurodevelopmental Pathways in Brain Tumors.Frontiers in cell and developmental biology · 2021
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Sabit DelicCorresponding author: Markus J. Riemenschneider, MD, Department of Neuropathology, Regensburg University Hospital, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany. markus.riemenschneider@ukr.de.
Nadine Lottmann
Anja Stelzl
Franziska Liesenberg
Marietta Wolter
Silke Götze
Marc Zapatka
Yuzuru Shiio
Michael C Sabel
Jörg Felsberg
Guido Reifenberger
Markus J Riemenschneider
Heidelberg University · DEUniversity Hospital Regensburg · DEGerman Cancer Research Center · DEHeinrich Heine University Düsseldorf · DEMax Planck Institute of Molecular Physiology · DEThe University of Texas Health Science Center · USThe University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Diffusely infiltrative growth of human astrocytic gliomas is one of the major obstacles to successful tumor therapy. Thorough insights into the molecules and pathways signaling glioma cell invasion thus appear of major relevance for the development of targeted and individualized therapies. By miRNA expression profiling of microdissected human tumor biopsy specimens we identified miR-328 as one of the main miRNAs upregulated in invading glioma cells in vivo and further investigated its role in glioma pathogenesis. Methods We employed miRNA mimics and inhibitors to functionally characterize miR-328, 3' untranslated region luciferase assays, and T-cell factor/lymphoid enhancer factor reporter assays to pinpoint miR-328 targets and signaling pathways, and analyzed miR-328 expression in a large panel of gliomas. Results First, we corroborated the invasion-promoting role of miR-328 in A172 and TP365MG glioma cells. Secreted Frizzled-related protein 1 (SFRP1), an inhibitor of Wnt signaling, was then pinpointed as a direct miR-328 target. SFRP1 expression is of prognostic relevance in gliomas with reduced expression, being associated with significantly lower overall patient survival in both the Repository of Molecular Brain Neoplasia Data (REMBRANDT) and The Cancer Genome Atlas. Of note, miR-328 regulated both SFRP1 protein expression levels and Wnt signaling pathway activity. Finally, in human glioma tissues miR-328 appeared to account for the downregulation of SFRP1 preferentially in lower-grade astrocytic gliomas and was inversely related to SFRP1 promoter hypermethylation. Conclusion Taken together, we report on a novel molecular miR-328-dependent mechanism that via SFRP1 inhibition and Wnt activation contributes to the infiltrative glioma phenotype at already early stages of glioma progression, with unfavorable prognostic implications for the final outcome of the disease.

Indexed as

Cell MovementGene Expression Regulation, NeoplasticAdolescentAdultAgedApoptosisBlotting, WesternBrain NeoplasmsCell ProliferationDNA MethylationFemaleGliomaHumansImmunoenzyme TechniquesIntercellular Signaling Peptides and ProteinsMaleIntercellular Signaling Peptides and ProteinsMembrane ProteinsMicroRNAsMIRN328 microRNA, humanRNA, MessengerSecreted Frizzled-Related ProteinsSFRP1 protein, humanWnt Proteinsastrocytomabrain tumorepigeneticglioblastomamiRNA

Identifiers

PMID24305703
PMCPMC3895379
OpenAlexW2121878722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.